Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multi-Center Randomized, Double-Blind, Parallel Group, Placebo Controlled Study, Including an Additional Open Label Tiotropium Group, to Assess the Efficacy, Safety and Tolerability of 4 Doses of AD 237 Inhaled Once Daily for 28 Days in Subjects With COPD.

NCT00242333 is registered in ClinicalTrials.gov with Sosei as lead sponsor.

NCT NCT00242333
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00242333 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multi-Center Randomized, Double-Blind, Parallel Group, Placebo Controlled Study, Including an Additional Open Label Tiotropium Group, to Assess the Efficacy, Safety and Tolerability of 4 Doses of AD 237 Inhaled Once Daily for 28 Days in Subjects With COPD.
Lead sponsor
Sosei
Phase
Phase 2
Overall status
Completed
Start date
October 31, 2005
Completion date
Not reported
Enrollment
300
Sites
33

Conditions

As the registry lists them; a condition with its own page is linked.

copd